A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis
Open Access
- 13 August 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Genes & Immunity
- Vol. 11 (1), 1-10
- https://doi.org/10.1038/gene.2009.61
Abstract
Complement activation in myasthenia gravis (MG) may damage muscle endplate and complement regulatory proteins such as decay-accelerating factor (DAF) or CD55 may be protective. We hypothesize that the increased prevalence of severe extraocular muscle (EOM) dysfunction among African MG subjects reported earlier may result from altered DAF expression. To test this hypothesis, we screened the DAF gene sequences relevant to the classical complement pathway and found an association between myasthenics with EOM paresis and the DAF regulatory region c.-198C>G SNP (odds ratio=8.6; P=0.0003). This single nucleotide polymorphism (SNP) results in a twofold activation of a DAF 5′-flanking region luciferase reporter transfected into three different cell lines. Direct matching of the surrounding SNP sequence within the DAF regulatory region with the known transcription factor-binding sites suggests a loss of an Sp1-binding site. This was supported by the observation that the c.-198C>G SNP did not show the normal lipopolysaccharide-induced DAF transcriptional upregulation in lymphoblasts from four patients. Our findings suggest that at critical periods during autoimmune MG, this SNP may result in inadequate DAF upregulation with consequent complement-mediated EOM damage. Susceptible individuals may benefit from anti-complement therapy in addition to immunosuppression.Keywords
This publication has 62 references indexed in Scilit:
- Novel complement inhibitor limits severity of experimentally myasthenia gravisAnnals of Neurology, 2009
- How myasthenia gravis alters the safety factor for neuromuscular transmissionJournal of Neuroimmunology, 2008
- Extraocular Muscle Susceptibility to Myasthenia GravisAnnals of the New York Academy of Sciences, 2008
- Decay-Accelerating Factor Ameliorates Systemic Autoimmune Disease in MRL/lpr Mice via Both Complement-Dependent and -Independent MechanismsThe American Journal of Pathology, 2007
- Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytesImmunology, 2006
- The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in miceClinical and Experimental Immunology, 2006
- Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis ratsClinical and Experimental Immunology, 2006
- Quantification of mRNA using real-time RT-PCRNature Protocols, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Myasthenic Antibodies Cross-Link Acetylcholine Receptors to Accelerate DegradationNew England Journal of Medicine, 1978